NYSE:KOD - Kodiak Sciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$8.23 -0.43 (-4.97 %)
(As of 12/12/2018 04:00 PM ET)
Previous Close$8.66
Today's Range$7.77 - $8.56
52-Week Range$7.25 - $11.10
Volume38,400 shs
Average Volume69,738 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidates include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases; KSI-201, a recombinant mammalian cell expressed dual inhibitor antibody biopolymer bioconjugate for the treatment of wet AMD; and KSI-401, a recombinant mammalian cell expressed antibody biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.

Receive KOD News and Ratings via Email

Sign-up to receive the latest news and ratings for KOD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:KOD
Previous Symbol
CUSIPN/A
Phone650-281-0850

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees28
Outstanding Shares36,830,000
Market Cap$0.00
OptionableNot Optionable

Kodiak Sciences (NYSE:KOD) Frequently Asked Questions

What is Kodiak Sciences' stock symbol?

Kodiak Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "KOD."

How were Kodiak Sciences' earnings last quarter?

Kodiak Sciences Inc. (NYSE:KOD) announced its quarterly earnings results on Friday, November, 16th. The company reported ($1.33) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.26) by $1.07. View Kodiak Sciences' Earnings History.

When is Kodiak Sciences' next earnings date?

Kodiak Sciences is scheduled to release their next quarterly earnings announcement on Friday, February 15th 2019. View Earnings Estimates for Kodiak Sciences.

What price target have analysts set for KOD?

3 brokerages have issued 1-year price targets for Kodiak Sciences' stock. Their forecasts range from $14.00 to $20.00. On average, they expect Kodiak Sciences' stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 118.7% from the stock's current price. View Analyst Price Targets for Kodiak Sciences.

What is the consensus analysts' recommendation for Kodiak Sciences?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kodiak Sciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kodiak Sciences.

Has Kodiak Sciences been receiving favorable news coverage?

News headlines about KOD stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kodiak Sciences earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are some of Kodiak Sciences' key competitors?

Who are Kodiak Sciences' key executives?

Kodiak Sciences' management team includes the folowing people:
  • Dr. Victor Perlroth, Co-Founder, Chairman, CEO & Pres (Age 45)
  • Mr. John A. Borgeson MBA, CPA, Sr. VP & CFO (Age 57)
  • Dr. Hong Liang, Sr. VP of Discovery Medicine (Age 46)
  • Dr. Jason S. Ehrlich M.D., Ph.D., Chief Medical Officer & Chief Devel. Officer (Age 42)
  • Dr. Joel Naor M.D., MSc, MBA, VP of Clinical R&D Operations

When did Kodiak Sciences IPO?

(KOD) raised $126 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 9,000,000 shares at a price of $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Barclays and Chardan were co-managers.

When does the company's lock-up period expire?

Kodiak Sciences' lock-up period expires on Tuesday, April 2nd. Kodiak Sciences had issued 9,000,000 shares in its IPO on October 4th. The total size of the offering was $90,000,000 based on an initial share price of $10.00. After the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

How do I buy shares of Kodiak Sciences?

Shares of KOD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kodiak Sciences' stock price today?

One share of KOD stock can currently be purchased for approximately $8.23.

What is Kodiak Sciences' official website?

The official website for Kodiak Sciences is http://www.kodiak.com.

How can I contact Kodiak Sciences?

The company can be reached via phone at 650-281-0850.


MarketBeat Community Rating for Kodiak Sciences (NYSE KOD)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  17 (Vote Outperform)
Underperform Votes:  16 (Vote Underperform)
Total Votes:  33
MarketBeat's community ratings are surveys of what our community members think about Kodiak Sciences and other stocks. Vote "Outperform" if you believe KOD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KOD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel